

Date: February 10, 2022

To, The Manager, Listing Department, National Stock Exchange of India Limited (NSE), Exchange Plaza, C - 1, Block - G, Bandra - Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, BSE Limited, 1 st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai - 400 001.
Symbol - LINCOLN	Scrip Code - 531633

Dear Sir,

SUB.: OUTCOME OF BOARD MEETING.

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Thursday, February 10, 2022, have considered and approved the un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and nine months ended on December 31, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter.

Meeting of the Board of Directors commenced at 11:30 am and concluded at 12:45 pm.

Kindly take the same on your records.

Thanking you,

Yours faithfully,
For Lincoln Pharmaceuticals Limited

H.A. Desai



Niren A. Desai
Company Secretary &
Compliance Officer

Encl: A/a

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,


Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com

Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2021.

Sr. No.	Particulars	(₹ in Lakhs Except Per Share Data)					
		Quarter Ended			Nine Months Ended		Year Ended
		31/12/2021 (Un-Audited)	30/09/2021 (Un-Audited)	31/12/2020 (Un-Audited)	31/12/2021 (Un-Audited)	31/12/2020 (Un-Audited)	31/03/2021 (Audited)
1	Income						
	A) Revenue From Operations	11,988.03	12,746.75	11,463.26	36,953.65	34,334.40	42,290.85
	B) Other Income	263.54	346.06	75.29	810.68	336.22	574.85
	Total Income (1)	12,251.57	13,092.81	11,538.55	37,764.34	34,670.61	42,865.70
2	Expenses						
	A) Cost of Material Consumed	4,003.79	3,675.42	3,581.69	11,484.05	9,842.05	12,343.24
	B) Purchase of Stock-In-Trade	2,087.21	2,767.75	2,518.43	6,528.76	6,489.36	6,982.46
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	(509.42)	(446.05)	55.24	(699.03)	874.63	366.66
	D) Employee Benefits Expenses	1,706.99	1,582.74	1,380.14	4,987.52	4,034.41	6,067.79
	E) Finance Costs	30.52	20.39	39.04	88.46	98.48	155.23
	F) Depreciation and Amortisation Expense	218.10	199.19	189.59	608.97	566.86	756.02
	G) Other Expenses	2,354.45	2,239.79	1,931.12	6,848.90	5,933.51	7,827.17
	Total Expenses (2)	9,891.63	10,039.22	9,695.26	29,847.63	27,839.30	34,498.58
3	Profit / (Loss) Before Exceptional Items & Tax (1-2)	2,359.94	3,053.59	1,843.29	7,916.71	6,831.31	8,367.12
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
5	Profit / (Loss) after Exceptional Items but Before Tax (3-4)	2,359.94	3,053.59	1,843.29	7,916.71	6,831.31	8,367.12
6	Tax Expense						
	A) Current Tax	616.25	691.45	478.50	2,025.00	1,793.00	2,124.78
	B) Deferred Tax	24.55	(24.56)	16.03	15.60	60.42	24.72
	C) Short / (Excess) Tax Provision	(41.05)	84.03	Nil	42.98	10.13	(7.40)
7	Net Profit / (Loss) For The Period (5-6)	1,760.19	2,302.67	1,348.76	5,833.13	4,967.76	6,225.02
8	Other Comprehensive Income (Net Of Tax)						
	Items that will not be reclassified to subsequently to profit and loss	4.27	0.48	(11.55)	5.22	(34.64)	1.91
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil	Nil	Nil
9	Total Comprehensive Income	1,764.45	2,303.15	1,337.21	5,838.35	4,933.12	6,226.93
10	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97
11	Other Equity						34,495.31
12	Earnings Per Share (of Rs. 10/- Each) (Not Annualised)						
	(a) Basic (In ₹)	8.79	11.50	6.73	29.12	24.80	31.08
	(b) Diluted (In ₹)	8.79	11.50	6.73	29.12	24.80	31.08


- Notes:**
- The above standalone un-audited financial results of the Company for the quarter and nine months ended on December 31, 2021 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, February 10, 2022. The auditor have carried out an limited review of the said financial results.
 - This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
 - The Company has a single business segment namely 'Pharmaceutical Business'.
With respect to ad-interim relief granted by Hon'ble High Court of Gujarat on operation and implementation of the order passed by the Hon'ble National Company Law Tribunal, Ahmedabad Bench (Hon'ble NCLT) vide its order dated September 14, 2021, sanctioning the scheme of amalgamation of Lincoln Parenteral Limited ('Transferor Company') and Lincoln Pharmaceuticals Limited ('Transferee Company') and their respective shareholders and creditors ('Scheme').
 - Hon'ble High Court of Gujarat in its order dated January 04, 2022 had directed Hon'ble NCLT, to list the matter on January 12, 2022 for pronouncement and considering stay matter on the order dated September 14, 2021.
In this matter, Hon'ble NCLT vide its order dated January 12, 2022 passed an order and concluded that it is not fit case to grant stay to the operation and implementation of the scheme. In view of the same, these quarterly standalone financial result of the Lincoln Pharmaceuticals Ltd includes the figures of Lincoln Parenteral Ltd (Transferor or Amalgamating Company).
 - Pursuant to the scheme, Company has allotted 29,728 equity shares of face value of ₹ 10/- each during the quarter to the eligible shareholders of the erstwhile Transferor Company. Further, it is noted that the 98,58,438 equity shares of Transferor Company held by the Company (Transferee Company) cancelled without any act, deeds or instrument. However, Considering the appointed date of the scheme, The paid up share capital of the Company is considered after allotment of the said shares, so as to reflect correct EPS.
 - The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.

For Lincoln Pharmaceuticals Limited



M. Patel
Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: February 10, 2022



Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To

The Board of Directors of,

Lincoln Pharmaceuticals Limited,

Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Lincoln Pharmaceuticals Limited** ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad – 380060, Gujarat for the quarter ended December 31, 2021 and for the year to date period from April 01, 2021 to December 31, 2021 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations

J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad

Date: 10/02/2022



For, J.T. Shah & Co.

Chartered Accountants

(Firm Regd. No: 109616W)

(J. J. Shah)

Partner

(M.No.45669)

UDIN: 22045669ABDFXG8123

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com

Statement of Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2021.

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31/12/2021 (Un-Audited)	30/09/2021 (Un-Audited)	31/12/2020 (Un-Audited)	31/12/2021 (Un-Audited)	31/12/2020 (Un-Audited)	31/03/2021 (Audited)
1	Income						
	A) Revenue From Operations	11,988.03	12,746.75	11,474.71	36,953.65	34,460.50	42,418.54
	B) Other Income	263.54	346.06	72.92	810.68	312.90	566.39
	Total Income (1)	12,251.57	13,092.81	11,547.63	37,764.34	34,773.40	42,984.93
2	Expenses						
	A) Cost of Material Consumed	4,003.79	3,675.42	3,581.69	11,484.05	9,842.05	12,343.24
	B) Purchase of Stock-In-Trade	2,087.21	2,768.11	2,518.43	6,529.12	6,521.27	7,031.43
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	(509.42)	(446.05)	55.24	(699.03)	907.04	399.07
	D) Employee Benefits Expenses	1,706.99	1,582.74	1,380.14	4,987.52	4,034.41	6,073.79
	E) Finance Costs	30.52	20.40	39.16	88.48	98.69	156.17
	F) Depreciation and Amortisation Expense	218.10	199.19	189.59	608.97	566.86	756.02
	G) Other Expenses	2,354.45	2,239.41	1,939.03	6,848.53	5,962.27	7,853.12
	Total Expenses (2)	9,891.63	10,039.22	9,703.28	29,847.63	27,932.60	34,612.84
3	Profit / (Loss) Before Exceptional Items & Tax (1-2)	2,359.94	3,053.59	1,844.35	7,916.71	6,840.80	8,372.09
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
5	Profit / (Loss) after Exceptional Items but Before Tax (3-4)	2,359.94	3,053.59	1,844.35	7,916.71	6,840.80	8,372.09
6	Tax Expense						
	A) Current Tax	616.25	691.45	479.99	2,025.00	1803.58	2129.04
	B) Deferred Tax	24.55	(24.56)	16.03	15.60	60.42	24.72
	C) Short / (Excess) Tax Provision	(41.05)	84.03	Nil	42.98	10.13	(6.69)
7	Net Profit / (Loss) For The Period (5-6)	1,760.19	2,302.67	1,348.32	5,833.13	4,966.67	6,225.02
8	Attributable to Non-Controlling Interest	(0.67)	0.22	0.14	Nil	1.56	2.61
	Attributable to Owners of the Company	1,760.85	2,302.45	1,348.18	5,833.13	4,965.11	6,222.41
9	Other Comprehensive Income (Net Of Tax)						
	Items that will not be reclassified to subsequently to profit and loss	4.27	0.48	(11.55)	5.22	(34.64)	1.91
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil	Nil	Nil
10	Total Comprehensive Income	1,764.45	2,303.15	1,336.78	5,838.35	4,932.04	6,226.93
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97	2,002.97
12	Other Equity						35,529.21
13	Earnings Per Share (of Rs. 10/- Each) (Not Annualised)						
	(a) Basic (In ₹)	8.79	11.50	6.73	29.12	24.79	31.07
	(b) Diluted (In ₹)	8.79	11.50	6.73	29.12	24.79	31.07

Notes:

- The above consolidated un-audited financial results of the Company for the quarter and nine months ended on December 31, 2021 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, February 10, 2022. The auditor have carried out an limited review of the said financial results.
- This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- Pursuant to the scheme, Company has allotted 29,728 equity shares of face value of ₹ 10/- each during the quarter to the eligible shareholders of the erstwhile Transferor Company. Further, it is noted that the 98,58,438 equity shares of Transferor Company held by the Company (Transferee Company) cancelled without any act, deeds or instrument. However, Considering the appointed date of the scheme, The paid up share capital of the Company is considered after allotment of the said shares, so as to reflect correct EPS.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
- Consolidated results includes results of one subsidiary namely Zullinc Healthcare LLP.

For Lincoln Pharmaceuticals Limited

Place: Ahmedabad
Date: February 10, 2022



M. Patel
Mahendra G. Patel
Managing Director
DIN: 00104706



Limited Review Report on consolidated unaudited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To

The Board of Directors of,
Lincoln Pharmaceuticals Limited,
Ahmedabad

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Lincoln Pharmaceuticals Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2021 and for the year to date period from April 01, 2021 to December 31, 2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

4. The Statement includes the results of the following entities:

- | | | |
|------------------------------------|---|-------------------------|
| A. Lincoln Pharmaceuticals Limited | - | Parent Company |
| B. Zullinc Healthcare LLP | - | Wholly-Owned Subsidiary |

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of two subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflects total revenues of Rs. Nil Lacs, total net Loss of Rs. 1.39 Lacs for the nine months ended December 31, 2021, as considered in the statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the statement in respect of matters stated in para 6 above is not modified.

Place: Ahmedabad

Date: 10/02/2022



For, J.T. Shah & Co.
Chartered Accountants
(Firm Regd. No: 109616W)

(J. J. Shah)

Partner

(M.No.45669)

UDIN: 22045669ABDGVT1569

Media Release

Lincoln Pharmaceuticals Ltd reports 30.50% rise in the Standalone Net Profit at ₹ 17.60 crore in Q3 FY22

Highlights:-

- Net revenues in Q3 FY22 at ₹ 122.52 crore, up 6.18% from ₹ 115.39 crore in Q3 FY21;
- Exports (FOB) in 9MFY22 at ₹ 199.78 crore;
- Over the last 5 years, company has delivered a robust 20% plus CAGR in profits.


Financial Highlights (Standalone)

(Amount in Cr except EPS)

	Q3 FY22	Q3 FY21	Y-O-Y	9M FY22	9M FY21	Y-O-Y
Net Revenue from Operations	122.52	115.39	6.18%	377.64	346.71	8.92%
EBITDA	26.09	20.72	25.90%	86.14	74.97	14.91%
Profit before Tax	23.60	18.43	28.03%	79.17	68.31	15.89%
Net Profit	17.60	13.49	30.50%	58.33	49.68	17.42%
E.P.S (₹)	8.79	6.73	30.50%	29.12	24.80	17.42%

February 10, 2022: Lincoln Pharmaceuticals Ltd, one of India's leading healthcare companies has reported net profit of ₹ 17.60 crore for the Q3 FY22 ended December 2021 as against net profit of ₹ 13.49 crore in the corresponding period last year, growth of 30.50%. Net revenue for the Q3 FY22 was reported at ₹ 122.52 crore, higher by 6.18% over previous fiscal's same period net revenue of ₹ 115.39 crore. Company reported EBITDA of ₹ 26.09 crore in Q3FY22, rise of 25.90% as compared to ₹ 20.72 crore in the corresponding period last year. EPS for Q3FY22 was at ₹ 8.79 per share for as compared to ₹ 6.73 in the corresponding period last year.

Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd, said, "Company is progressing well on its long-term growth roadmap and we are pleased with the performance so far. Our international business is complementing well with our domestic business to further cement our position in the industry. Progress on the Mehsana expansion for the launch of Cephalosporin products is going as per schedule. Going forward we are confident to improve our growth numbers on all fronts. Strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximize value for all stakeholders in the near to medium term."



Regd. Office : "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380 060, Gujarat, India.
Phone : +91-79-4107 8000 | **CIN** L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : Trimul Estate, Khatraj-382721, Tal.-Kalol, Dist.- Gandhinagar, Gujarat, India.
Phone : +91-79-4913 5000 | **E-mail :** khatraj@lincolnpharma.com



Highlights: - 9MFY22 Results

For nine months ended December 2021, company reported net sales of ₹ 377.64 crore, higher by 8.92% over previous fiscal's same period net sales of ₹ 346.71 crore. Net profit of the company was reported at ₹ 58.33 crore for the nine months ended December 2021 as against net profit of ₹ 49.68 crore in the corresponding period last year, growth of 17.42%. EPS for the 9MFY22 was reported at ₹ 29.12 per share. Exports (FOB) in 9MFY22 at ₹ 199.78 crore.

Over the last 5 years, Lincoln Pharmaceuticals Ltd has delivered a robust 20% plus CAGR in profits and higher single digit growth in sales. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, no term debt and healthy return ratios. Backed by improvement in the company's financial risk profile, steady growth in scale & margins, healthy profitability, rating agency ICRA has upgraded the company's long-term and short-term bank facilities to A and A1 respectively.

Exports (FOB) in 9MFY22 at ₹ 199.78 crore. Export business of the company has shown remarkable growth in the last few years and had increased to 65% of total sales in FY21 from 11% of total sales in FY13. Company currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia. TGA - Australia and EU GMP approvals will further strengthen the company's presence and expand network to 90 plus countries. Company looks to enter the EU markets during the current financial year.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP, TGA - Australia and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. To complement company's strong presence in acute segment, company is also building portfolio in lifestyle and chronic segment especially dermatology, gastro and pain management. Company has filed 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.

About Lincoln Pharmaceuticals Ltd: <https://www.lincolnpharma.com/>

Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Ltd is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus



formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create "Healthcare for All".

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EU GMP, WHO-GMP and ISO-9001: 2015. Recently the company has also received an approval from Australia's medicines and medical devices regulator - Therapeutic Goods Administration (TGA). TGA and EU GMP approvals will further strengthen the company's presence in the export market from 60 plus countries to over 90 plus countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country. Company has a wide national distribution network through 21+ Super Stockist and over 50,000 retailers in 26 states across India.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

For further information please contact:

Gopal Modi / Rupesh Panchal
ColdCoco Consultancy, Ahmedabad
9099030184 / 9925023103
gopal@coldcococonsultancy.com
rupesh@coldcococonsultancy.com

Darshit A. Shah (CFO)
Lincoln Pharmaceuticals Ltd, Ahmedabad
+91-79-4107-8048
darshit@lincolnpharma.com

